Prevention of meningococcal serogroup C disease by NeisVac-C.

NeisVac-C has been demonstrated to be safe, immunogenic and efficacious when administered to infants, toddlers, older children and adults. It is one of the licensed meningococcal serogroup C conjugate vaccines and a single dose in infancy may be sufficient for protection until a booster dose is given in the second year of life. Persistence of serum bactericidal antibody, rather than immune memory, is now known to be a more appropriate correlate of long-term protection for serogroup C meningococcal disease. NeisVac-C was demonstrated to enhance responses to Haemophilus influenzae type b (Hib) polyribosylribitol phosphate when coadministered with Hib-tetanus toxoid conjugate vaccines. NeisVac-C also enhances tetanus toxid responses and a dose of NeisVac-C in older children induces responses similar to a dose of tetanus toxoid vaccine.